Trial success boosts NovoCure

Asaf Danziger credit: PR
Asaf Danziger credit: PR

The company's share price is up over 30% after it announced the results of the trial of its product in treating pancreatic cancer.

NovoCure (Nasdaq: NVCR) announced good results today in its trial of a treatment for pancreatic cancer. The announcement follows the approval granted two months ago for the sale of its treatment for lung cancer. NovoCure’s share price is currently up by more than 30% on Nasdaq, giving the company a market cap of $2.83 billion. The share price is up by 82% for the year to date, after a period of decline.

NovoCure’s trial was conducted on a group of patients with an advanced stage of local pancreatic cancer that could not be surgically removed. The trial group was treated with NovoCure’s product in combination with chemotherapy. The primary endpoint in the trial was the survival rate of patients, and it was clearly met. The proportion of patients still alive in the treated group after two years was 33% higher than in the control group. Median overall survival in the group treated with NovoCure’s product was 16.2 months, which compares with 14.2 months with standard treatment of chemotherapy alone.

Two additional months of life may not sound like much, but that is the median figure, and for some of the patients the gain was greater. NovoCure chief medical officer Nicolas Leupin said, "PANOVA-3 is the first and only Phase 3 trial to demonstrate a statistically significant benefit in overall survival specifically in unresectable, locally advanced pancreatic cancer, and is NovoCure’s third positive Phase 3 clinical trial in the last two years."

On the basis of the trial results, NovoCure will file for regulatory approval of its product, probably next year.

No comparison was carried out in this trial with immunotherapy treatment, a newer method of treatment than chemotherapy approved for use in a small proportion of pancreatic cancer patients. The results of an additional trial, of Novocure’s product in combination with immunotherapy, are expected to be published in 2026.

NovoCure has produced a system for treatment of cancerous cells with focused electric fields - Tumor Treating Fields (TTF) - developed by Prof. Yoram Palti, professor emeritus of physiology and biophysics at the Technion - Israel Institute of Technology, and chief technology officer at NovoCure. The company’s leading product is a helmet for treating glioblastoma (GBM), a form of brain cancer.

In the third quarter of this year, NovoCure had revenue of $166 million, representing 122% growth over the corresponding quarter. In the past few quarters, the company has posted losses because of its high level of investment in development. It has $90 million cash.

Now, the company is aiming at two larger markets. The lung cancer market is ten times larger than the GBM market, and the pancreatic cancer market is five times larger. Novocure is not expected to address the whole market immediately, but rather to expand gradually among patients for whom the treatment is relevant, as it did with brain cancer.

NovoCure recently announced that Asaf Danziger, its CEO for 22 years, almost from the day it was founded, will step down, and will be replaced by the company’s CFO, Ashley Cordova.

Published by Globes, Israel business news - en.globes.co.il - on December 2, 2024.

© Copyright of Globes Publisher Itonut (1983) Ltd., 2024.

Asaf Danziger credit: PR
Asaf Danziger credit: PR
Inflation  credit: Tali Bogdanovsky Unexpectedly low February CPI reading cuts inflation

While inflation in Israel in the 12 months to the end of February 2025 is lower than forecast, housing prices continue to rise.

Yitzhak Tshuva credit: Gidon Levy and Tali Bogdanovsky Competition Authority allows Delek takeover of Isracard

The Competition Authority is considered the easier of the two regulatory hurdles that the deal must overcome, the other being the Supervisor of Banks.

David Amsalem  credit  Noam Moskowitz, Knesset Spokesperson's Office Rafael to pay state NIS 444m dividend

The minister in charge of the Government Companies Authority, David Amsalem, has approved the payment by the defense company.

Barak MX air defense system  credit: IAI IAI profit jumps 55%

Israel Aerospace Industries posted a net profit of $493 million for 2024, and ended the year with an all-time high orders backlog of $25 billion.

A TSG system in tactical use  credit: PR TSG signs cooperation agreement with US defense co

The agreement includes the integration of TSG's advanced technologies into sensor-based defense systems, which will be integrated into the operational systems of US defense units.

Bria CEO Yair Adato credit: Kseniia Poliak Israeli visual generative AI co Bria raises $40m

Bria’s Visual Generative AI platform empowers businesses to create predictable, controllable, and on-brand content that aligns with their visual language.

Amnon Shashua and Aviram Ziv credit: Eyal Izhar OrCam stymied by investor dispute with Shashua

Demands by institutional investors are blocking the visual and hearing impairment device developer's recovery plan.

Work on the Green Line credit: Bar Lavi Egged wins tender to operate TA light rail Purple, Green Lines

NTA awarded the tender to Egged, which already operates the Red Line, despite government ministry opposition to one operator for the entire network.

Gabi Seroussi illustration: Gil Gibli Board chooses Seroussi as IAI chair as Erdan freezes candidacy

Israel Aerospace Industries board chose Gabi Seroussi as chair even though he did not to go through the preliminary process of the Government Companies Authority appointments review committee.

Bavli Park penthouse credit: Eyal Tagar Tel Aviv Park Bavli penthouse sells for NIS 43m

A 44th floor penthouse in one of the two towers in businessman Yitzhak Tshuva's Park Bavli project has been bought by an Israeli businessperson.

El Al aircraft  credit: Yoav Yaari El Al pilots receive nearly NIS 250,000 bonus each

Thanks to the agreements signed with the unions in 2018, El Al's employees as well as senior management share in last year's success.

Pentera CEO Amitai Ratzon credit: Eyal Izhar Israeli security validation co Pentera raises $60m

Pentera's platform enables security teams to analyze complete attack paths, identify root causes, and prioritize remediation for effective risk reduction.

Tel Aviv credit: Shutterstock Supply of unsold new homes hits record

Israel's real estate market is sliding into recession with 78,000 unsold new apartments in January, the Central Bureau of Statistics reports.

D&B chairman Doron Cohen and Meitar partner Dan Geva Meitar reclaims title of Israel's biggest law firm

Meitar has first place with 537 lawyers, followed by Herzog Fox Neeman with 512 lawyers, according to the latest Dun's 100 rankings.

First International Bank of Israel CEO Eli Cohen  credit: Eyal Toueg First Int'l posts top return on equity

First International Bank of Israel's return on equity in 2024 was 19%, the highest among Israel's banks.

Dina Ben Tal Ganancia  credit: Guy Kushi & Yariv Fein El Al almost quintuples profit

The airline posted a net profit of $545 million for 2024, 4.7 times the profit in 2023, and an all-time high.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018